关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
' a0 l# |8 i9 D# O    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
  k3 B! f# \; o; g$ Q. V1 `
作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
7 M2 a3 O! M0 C0 H, ^3 i" [Dear Group,
9 V0 T% o; X' m* o7 L4 q
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
! h' J2 a) P* i5 U# K8 ?. b1 J9 qtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
: \* n' @# u) I1 Vremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.

/ E! J! ]& a9 U( l  b6 H+ `; e5 S) MThe remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
" n& S' f. G1 f* n) b# gdifferent from the stopping Gleevec trial in France which only targets patients
: p8 Z# v; ]. Lwho have done well on Gleevec.
) D0 _$ J" D: s. ~/ l# i, T- e
2 e4 {) W9 U# UHopefully, the doctors will report on a larger study and long-term to see if the
, `0 u4 S$ ^& G2 O# Cresponse off Sprycel is sustained.
. ?4 k8 e1 E8 b: e0 }/ h# \
Best Wishes,
Anjana

, `$ e: O6 F$ n3 r! d( B  F
) v, i; S% p0 z" S8 @4 U
' j7 X% y  V2 Q8 D# l% I/ v1 jHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
/ k9 Z9 o9 n0 J) b9 W2 w9 qRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
; q2 W: m! E* J4 e9 @6 u6 AAdelaide, Australia;
  V4 E) }3 e1 V+ `7 Q
! x. h3 R$ U2 U0 n2 |Abstract
5 q. w+ j- b) x( I  u& kPatients with chronic myeloid leukemia, treated with imatinib, who have a
4 T2 N" ~$ P4 x$ Q( A  Ydurable complete molecular response might remain in CMR after stopping
6 H" @9 n4 V" l6 s% a) F6 S* xtreatment. Previous reports of patients stopping treatment in complete molecular
# E- u+ E7 j7 b8 X  bresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
3 U- A1 m" Q' ?* \4 m( \  ztreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
' i3 f( ~2 Z/ G7 K/ X+ ^imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
: F) x- S2 G, O3 S9 Tcharacteristics of complete molecular response on dasatinib treatment may be
; ]- t; N8 ~4 h; G# S0 K0 h: O- e# Asimilar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事